Everything below concerns tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
=== 2000–2010: Further expansion === In 2001, Henry McKinnell became CEO, replacing William C. Steere, Jr. In 2002, The Bill & Melinda Gates Foundation purchased stock in Pfizer. In 2004, the company received approval for Lyrica (pregabalin), an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. The United States patent on Lyrica was challenged by generic manufacturers and was upheld in 2014, extending the expiration date to 2018. In July 2006, Jeff Kindler was named CEO, replacing Henry McKinnell. On December 3, 2006, Pfizer ceased development of torcetrapib, a drug that increases production of HDL, which reduces LDL thought to be correlated to heart disease. During a Phase III clinical trial involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the mortality rate of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1 billion developing the failed drug and its stock price dropped 11% on the day of the announcement. Between 2007 and 2010, Pfizer spent $3.3 million on investigations and legal fees and recovered about $5.1 million, and had another $5 million of pending recoveries from civil lawsuits against makers of counterfeit prescription drugs.
== Further reading == Beck, M. T.; Kauffman, G. B. (1985). "COS and C3S2: The Discovery and Chemistry of Two Important Inorganic Sulfur Compounds". Polyhedron. 4 (5): 775–781. doi:10.1016/S0277-5387(00)87025-4. J. Elliott Campbell; Jürgen Kesselmeier; Dan Yakir; Joe A. Berry; Philippe Peylin; Sauveur Belviso; Timo Vesala; Kadmiel Maseyk; Ulrike Seibt; Huilin Chen; Mary E. Whelan; Timothy W. Hilton; Stephen A. Montzka; Max B. Berkelhammer; Sinikka T. Lennartz; Le Kuai; Georg Wohlfahrt; Yuting Wang; Nicola J. Blake; Donald R. Blake; James Stinecipher; Ian Baker; Stephen Sitch (2017). "Assessing a New Clue to How Much Carbon Plants Take Up". EOS. 98. doi:10.1029/2017EO075313. hdl:10871/31921. Svoronos P. D. N.; Bruno T. J. (2002). "Carbonyl sulfide: A review of its chemistry and properties". Industrial & Engineering Chemistry Research. 41 (22): 5321–5336. doi:10.1021/ie020365n.
=== Emerald Twilight and beyond === In Emerald Twilight, Hal Jordan is driven to insanity and becomes the villain Parallax following the destruction of his hometown Coast City. He attacks Boodikka, cuts off her right hand, and takes her power ring, leaving her for dead. Boodikka is later revealed to have survived, but has been placed in suspended animation by the Manhunters along with many other former Green Lanterns, with the Manhunters intending to harness their energy to create more advanced Manhunters. After being freed, Boodikka is shocked that she no longer has her hand, and appears to remember nothing past her encounter with Parallax. During a later confrontation with the Manhunters, Kreon is killed and his ring chooses Boodikka. She resumes her duties in the Green Lantern Corps, replacing her lost hand with a Lantern construct.
=== Physical methods === Heat treatment − Treating food with heat, such as blanching or roasting, de-naturates enzymes and destroys the reactants responsible for browning. Blanching is used, for example, in winemaking, tea processing, storing nuts and bacon, and preparing vegetables for freezing preservation. Meat is often partially browned under high heat before being incorporated into a larger preparation to be cooked at a lower temperature which produces less browning. Cold treatment − Refrigeration and freezing are the most common ways of storing food, preventing decay. The activity of browning enzymes, i.e., rate of reaction, drops in low temperatures. Thus, refrigeration helps to keep the initial look, color, and flavour of fresh vegetables and fruits. Refrigeration is also used during distribution and retailing of fruits and vegetables. Oxygen elimination − Presence of oxygen is crucial for enzymatic browning, therefore eliminating oxygen from the environment helps to slow down the browning reaction. Withdrawing air or replacing it with other gases (e.g., N2 or CO2) during preservation, such as in vacuum-packaging or modified atmosphere packaging, wine or juice bottling, using impermeable films or edible coatings, dipping into salt or sugar solutions, keeps the food away from direct contact with oxygen. Impermeable films made of plastic or other materials prevent food being exposed to oxygen in the air and avoid moisture loss.
Sources: en.wikipedia.org
This single-exon gene was then duplicated in the stem amniote into the three subclasses of interferons, Ia (alpha, beta, delta, epsilon, sigma, nu, omega) Ib (kappa), and Ic (subsequently lost in mammals). The evolution of the Type I IFNs was characterized by extensive gene duplication and non-allelic homologous recombination (NAHR) between the many copies. The NAHR causes further duplication and also homogenizes the blocks by gene conversion. In catarrhine primates (including humans), the region between IFNA14 and IFNA21 remains a recombination hotspot. The evolution of types II and III in amniotes had been a lot less eventful as they generally stayed in the same location from shark to amniotes (between DYRK2 and IL22 for type II, near SYCN, SUPT5H, or TIMM50 for type III), with the exception of the birds and reptiles having duplicated their type II to the so-called IFNLB loci. The loss of introns in type III IFNs happened independently in a few tetrapod groups. Type IV (upsilon) stayed in the same location between the zebrafish and the chicken (between ADARB2 and PFKP) but was lost in humans. The nomenclature of interferons is inconsistent between species, growing in chaoticness as the distance from humans increase. For example, among reptiles, "IFN I" refers to interferon Type Ic and "IFN III" and "IFN IV" are sibling branches of type Ia. Due to the many gene conversion events, using the sequence alone does not always show the correct gene-to-gene correspondence (orthology) and colinearity is needed.
A 2011 review found that caffeine during pregnancy does not appear to increase the risk of congenital malformations, miscarriage or growth retardation even when consumed in moderate to high amounts. Other reviews concluded that there is some evidence that higher caffeine intake by pregnant women may be associated with a higher risk of giving birth to a low birth weight baby, and may be associated with a higher risk of pregnancy loss. A meta-analysis found a correlation between childhood obesity and maternal caffeine intake during pregnancy. A systematic review analyzed the results of observational studies, and found that women who consumed large amounts of caffeine (greater than 300 mg/day) prior to becoming pregnant may have had a higher risk of experiencing pregnancy loss.
SSRIs are effective for the treatment of premature ejaculation. Taking SSRIs on a chronic, daily basis is more effective than taking them prior to sexual activity. The increased efficacy of treatment when taking SSRIs on a daily basis is consistent with clinical observations that the therapeutic effects of SSRIs generally take several weeks to emerge. Sexual dysfunction ranging from decreased libido to anorgasmia is usually considered to be a significantly distressing side effect which may lead to noncompliance in patients receiving SSRIs. However, for those with premature ejaculation, this same side effect becomes the desired effect.
Datopotamab deruxtecan, sold under the brand name Datroway, is an anti-cancer medication used for the treatment of breast cancer. It is a Trop-2-directed antibody and topoisomerase inhibitor antibody-drug conjugate. The most common adverse reactions, including laboratory abnormalities, include stomatitis, nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, increased ALT, keratitis, increased AST, and increased alkaline phosphatase. Datopotamab deruxtecan was approved for medical use in the United States in January 2025, and in the European Union in April 2025.
=== Research fraud === Bharat Aggarwal, a former cancer researcher at the University of Texas MD Anderson Cancer Center, had 29 papers retracted due to research fraud as of July 2021. Aggarwal's research had focused on potential anti-cancer properties of herbs and spices, particularly curcumin, and according to a March 2016 article in the Houston Chronicle, "attracted national media interest and laid the groundwork for ongoing clinical trials". Aggarwal cofounded a company in 2004 called Curry Pharmaceuticals based in Research Triangle Park, North Carolina, which planned to develop drugs based on synthetic analogs of curcumin. SignPath Pharma, a company seeking to develop liposomal formulations of curcumin, licensed three patents by Aggarwal related to that approach from MD Anderson in 2013.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.